Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 12, 2009, Pages 1869-1875

  Kim, Young Choon ^a   Kim, Hong Joo ^a   Park, Jung Ho ^a   Park, Dong Il ^a   Cho, Yong Kyun ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a   Shin, Jun Ho ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Carbohydrate antigen 19 9; Carcinoembryonic antigen; Pancreatic adenocarcinoma; Resectability

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ACCURACY; AGED; ARTICLE; BYPASS SURGERY; CALCIUM BLOOD LEVEL; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PALLIATIVE THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; TUMOR VOLUME;

EID: 72149107632     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05935.x     Document Type: Article

References (39)

1. Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. 2001 234 : 758 768.
2. Okamoto A, Tsuruta K, Karasawa K et al. Resection versus palliation: treatment of stage III and IVA carcinomas of the pancreas employing intraoperative radiation. World J. Surg. 2003 27 : 599 605.
3. Baulieux J, Delpero JR. Surgical treatment of pancreatic cancer: curative resections. Ann. Chir. 2000 125 : 609 617.
4. Beger HG, Gansauge F, Leder G. Pancreatic cancer: who benefits from curative resection? Can. J. Gastroenterol. 2002 16 : 117 120.
5. Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J. Hepatobiliary Pancreat. Surg. 2004 11 : 4 10.
6. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J. Gastroenterol. Hepatol. 2008 23 : 23 33.
7. Vogt DP. Pancreatic cancer: a current overview. Curr. Surg. 2000 57 : 214 220.
8. Magee CJ, Ghanch P, Neoptolemos JP. Surgical and medical therapy for pancreatic carcinoma. Best Pract. Res. Clin. Gastroenterol. 2002 16 : 435 455.
9. Cappelli G, Paladini S, D'Agata A. Tumor markers in the diagnosis of pancreatic cancer. Tumori 1999 85 (1 Suppl 1 S19 21.
10. Civardi G, Cerri L, Cavanna L, Fornari F, Di Stasi M, Binelli F. Diagnostic accuracy of a new tumor serologic marker, CA 19-9: comparison with CEA. Tumori 1986 72 : 621 624.
11. Del Favero G, Fabris C, Plebani M et al. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986 57 : 1576 1579. (Pubitemid 16135606)
12. Frebourg T, Bercoff E, Manchon N et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988 62 : 2287 2290.
13. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br. J. Cancer 1994 69 : 515 519.
14. Safi F, Schlosser W, Falkenreck S, Beger HG. CA 19-9 serum course and prognosis of pancreatic cancer. Int. J. Pancreatol. 1996 20 : 155 161.
15. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch. Surg. 2003 138 : 951 955.
16. Greene FL, Page DL, Flemming ID et al. Pancreatic adenocarcinoma. In : The American Joint Committee on Cancer Staging Handbook, 6th edn. New York : Springer, 2002.
17. Elferink RP. Understanding and controlling hepatobiliary function. Best Pract. Res. Clin. Gastroenterol. 2002 16 : 1025 1034.
18. Raymond E, Boige V, Faivre S et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J. Clin. Oncol. 2002 20 : 4303 4312.
19. Haller DG. New perspectives in the management of pancreas cancer. Semin. Oncol. 2003 30 (4 Suppl. 11 3 10.
20. Ellsmere J, Mortele K, Sahani D et al. Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma? Surg. Endosc. 2005 19 : 369 373.
21. Gulliver DJ, Baker ME, Cheng CA et al. Malignant biliary obstruction: efficacy of thin-section dynamic CT in determining resectability. Am. J. Roentgenol. 1992 159 : 503 507.
22. Prokesch RW, Chow LC, Beaulieu CF et al. Isoattenuating pancreatic adenocarcinoma at multi detector row CT: secondary signs. Radiology 2002 224 : 764 768.
23. Saldinger PF, Reilly M, Reynolds K et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J. Gastrointest. Surg. 2000 4 : 233 237.
24. Spitz FR, Abbruzzese JL, Lee JE et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J. Clin. Oncol. 1997 15 : 928 937.
25. Steinberg WM, Barkin J, Bradley EL, 3rd. et al. Workup of a patient with a mass in the head of the pancreas. Pancreas 1998 17 : 24 30.
26. Diehl SJ, Lehmann KJ, Sadick M et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998 206 : 373 378.
27. Friess H, Kleeff J, Silva JC et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J. Am. Coll. Surg. 1998 186 : 675 682.
28. Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J. Gastrointest. Surg. 1997 1 : 236 243.
29. Rumstadt B, Schwab M, Schuster K et al. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J. Gastrointest. Surg. 1997 1 : 245 250.
30. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin. Gastroenterol. Hepatol. 2008 12 : 1301 1308.
31. Kiliç M, Göçmen E, Tez M, Ertan T, Keskek M, Koç M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can. J. Surg. 2006 49 : 241 244.
32. Fujioka S, Misawa T, Okamoto T et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J. Hepatobiliary Pancreat. Surg. 2007 14 : 539 544.
33. Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J. Gastroenterol. 2008 14 : 3750 3753.
34. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983 43 : 5489 5492.
35. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998 45 : 253 259.
36. Mann DV, Edwards R, Ho S et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur. J. Surg. Oncol. 2000 26 : 474 479.
37. Cerwenka H, Aigner R, Quehenberger F et al. Preoperative differential diagnosis of benign and malignant pancreatic lesions-the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B. CA19-9 and CEA. Hepatogastroenterology 1997 44 : 1117 1121.
38. Ritts RE, Pitt HA. CA19-9 in pancreatic cancer. Surg. Oncol. Clin. N. Am. 1998 7 : 93 101.
39. Mery CM, Duarte-Rojo A, Paz-Pineda F, Gomez E, Robles-Diaz G. Does cholestasis change the clinical usefulness of CA19-9 in pancreatobiliary cancer? Rev. Invest. Clin. 2001 53 : 511 517.